Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242970 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL1415730 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL576868 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL8188324 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL1041303 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL2489199 | 0.80 | SIGMAR1 (1.00) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL28353107 | 0.78 | SIGMAR1 (0.69) | SIGMAR1MC4RLMNADRD4POLB | |
| Water SCHEMBL8695926 | 0.78 | SIGMAR1 (0.95) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL2228267 | 0.76 | SIGMAR1 (0.81) | SIGMAR1MC4RLMNADRD4POLB | |
| SCHEMBL1045330 | 0.76 | SIGMAR1 (0.81) | SIGMAR1MC4RLMNADRD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | SIGMAR1 106/4885MC4R 4/4885LMNA 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.